Proteases-From Basic Structure to Function to Drug Design as Targeted Therapy
In the two last decades, proteases have constituted one of the primary and important targets in drug discovery. The U.S. FDA has approved more than 12 protease therapies in the last 10 years, and a number of next-generation or completely new proteases are under clinical development. Protease inhibit...
Kaydedildi:
Diğer Yazarlar: | , , |
---|---|
Materyal Türü: | Elektronik Kitap Bölümü |
Dil: | İngilizce |
Baskı/Yayın Bilgisi: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
Konular: | |
Online Erişim: | DOAB: download the publication DOAB: description of the publication |
Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_77096 | ||
005 | 20220111 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20220111s2021 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-0365-2574-7 | ||
020 | |a 9783036525754 | ||
020 | |a 9783036525747 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-0365-2574-7 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a GP |2 bicssc | |
100 | 1 | |a Kwok, Hang Fai |4 edt | |
700 | 1 | |a Shaw, Christopher |4 edt | |
700 | 1 | |a Walker, Brian |4 edt | |
700 | 1 | |a Kwok, Hang Fai |4 oth | |
700 | 1 | |a Shaw, Christopher |4 oth | |
700 | 1 | |a Walker, Brian |4 oth | |
245 | 1 | 0 | |a Proteases-From Basic Structure to Function to Drug Design as Targeted Therapy |
260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
300 | |a 1 electronic resource (93 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a In the two last decades, proteases have constituted one of the primary and important targets in drug discovery. The U.S. FDA has approved more than 12 protease therapies in the last 10 years, and a number of next-generation or completely new proteases are under clinical development. Protease inhibition strategies are one of the fastest expanding areas in the field of of drugs that show considerable promise. This Special Issue will focus on the recent advances in the discovery and development of protease inhibitors, covering the synthesis of protease inhibitors, the design of new chemical entities acting as inhibitors of special/particular types of proteases, and their mode of actions (Frolova et al. 2020; Slapak et al. 2020; Künnapuu et al. 2021). In addition, the new applications of these interesting compounds/biomolecules and their limitations have been discussed and described (Wang et al. 2020; Bartošová-Sojková et al. 2021). | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Research & information: general |2 bicssc | |
653 | |a MMP | ||
653 | |a MMP2 | ||
653 | |a MMP9 | ||
653 | |a MMP7 | ||
653 | |a MMP14 | ||
653 | |a matrix metalloproteases | ||
653 | |a PDAC | ||
653 | |a pancreatic cancer | ||
653 | |a Bowman-Birk inhibitor | ||
653 | |a ranacyclin | ||
653 | |a trypsin inhibitor | ||
653 | |a structure-activity relationship | ||
653 | |a synergistic effect | ||
653 | |a Gentamicin | ||
653 | |a matrix metalloproteinase | ||
653 | |a extracellular matrix | ||
653 | |a nuclei | ||
653 | |a cancer | ||
653 | |a apoptosis | ||
653 | |a immune response | ||
653 | |a cysteine protease inhibitor | ||
653 | |a stefin | ||
653 | |a signal peptide | ||
653 | |a parasite | ||
653 | |a phylogenetic analysis | ||
653 | |a diversification | ||
653 | |a protein structure | ||
653 | |a vascular endothelial growth factors (VEGFs) | ||
653 | |a VEGF-A | ||
653 | |a PlGF | ||
653 | |a VEGF-B | ||
653 | |a VEGF-C | ||
653 | |a VEGF-D | ||
653 | |a angiogenesis | ||
653 | |a lymphangiogenesis | ||
653 | |a CCBE1 | ||
653 | |a proteases | ||
653 | |a ADAMTS3 | ||
653 | |a plasmin | ||
653 | |a cathepsin D | ||
653 | |a KLK3 | ||
653 | |a prostate-specific antigen (PSA) | ||
653 | |a thrombin | ||
653 | |a wound healing | ||
653 | |a metastasis | ||
653 | |a proteolytic activation | ||
653 | |a vascular biology | ||
653 | |a lymphedema | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/4715 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/77096 |7 0 |z DOAB: description of the publication |